These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 19091004)

  • 1. Requirements for a lead compound to become a clinical candidate.
    Hefti FF
    BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S7. PubMed ID: 19091004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons learned from candidate drug attrition.
    Empfield JR; Leeson PD
    IDrugs; 2010 Dec; 13(12):869-73. PubMed ID: 21154145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meeting the demands of regulatory requirements: the significance of ADME.
    Guttendorf R
    Bioanalysis; 2012 Jun; 4(12):1395-7. PubMed ID: 22793021
    [No Abstract]   [Full Text] [Related]  

  • 5. De-risking drug discovery with ADDME -- avoiding drug development mistakes early.
    Tsaioun K; Jacewicz M
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():47-55. PubMed ID: 19807206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
    Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
    Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving lead generation success through integrated methods: transcending 'drug discovery by numbers'.
    Campbell JB
    IDrugs; 2010 Dec; 13(12):874-9. PubMed ID: 21154146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of exploratory drug metabolism and pharmacokinetics in new drug research: case study-selection of a thrombin receptor antagonist for development.
    Hsieh Y; Cheng KC; Wang Y; Chackalamannil S; Xia Y; Korfmacher WA; White RE
    Curr Pharm Des; 2009; 15(19):2262-9. PubMed ID: 19601827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing the challenge of chemically reactive metabolites in drug development.
    Park BK; Boobis A; Clarke S; Goldring CE; Jones D; Kenna JG; Lambert C; Laverty HG; Naisbitt DJ; Nelson S; Nicoll-Griffith DA; Obach RS; Routledge P; Smith DA; Tweedie DJ; Vermeulen N; Williams DP; Wilson ID; Baillie TA
    Nat Rev Drug Discov; 2011 Apr; 10(4):292-306. PubMed ID: 21455238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolite identification and profiling in drug design: current practice and future directions.
    Zhang Z; Zhu M; Tang W
    Curr Pharm Des; 2009; 15(19):2220-35. PubMed ID: 19601824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How do the top 12 pharmaceutical companies operate safety pharmacology?
    Ewart L; Gallacher DJ; Gintant G; Guillon JM; Leishman D; Levesque P; McMahon N; Mylecraine L; Sanders M; Suter W; Wallis R; Valentin JP
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):66-70. PubMed ID: 22510338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing Oral Bioavailability in Drug Discovery: An Overview of Design and Testing Strategies and Formulation Options.
    Aungst BJ
    J Pharm Sci; 2017 Apr; 106(4):921-929. PubMed ID: 27986598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug target validation: Hitting the target.
    Smith C
    Nature; 2003 Mar; 422(6929):341, 343, 345 passim. PubMed ID: 12646927
    [No Abstract]   [Full Text] [Related]  

  • 15. An industry perspective on tiered approach to the investigation of metabolites in drug development.
    Huskey SE; Li W; Mangold JB; Flarakos J
    Bioanalysis; 2014 Mar; 6(5):617-28. PubMed ID: 24620804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural products research: perspectives from a major pharmaceutical company.
    Borris RP
    J Ethnopharmacol; 1996 Apr; 51(1-3):29-38. PubMed ID: 9213624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive assessment of ADMET risks in drug discovery.
    Wang J
    Curr Pharm Des; 2009; 15(19):2195-219. PubMed ID: 19601823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
    Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
    Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of drug metabolism and pharmacokinetics for new drug development.
    Kim YG; Kang KW
    Arch Pharm Res; 2011 Nov; 34(11):1769-71. PubMed ID: 22139678
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.